Based in biology | Focused on function

Clinical Development

RAV12 - A therapeutic MAb for GI cancers

Raven is currently entering Phase 2 studies for RAV12, our lead therapeutic antibody in development for the treatment of adenocarcinomas.
Learn more about RAV12

Technology Platform

Our Platform

The Raven integrated technology platform creates an optimal starting point for developing a new drug by rapidly generating well-characterized monoclonal antibodies to proteins on the cell surface that can be used to quickly identify and validate targets.
Learn more about the platform

Raven is extending its technology platform to discover and develop a novel class of therapeutic antibodies based on a new approach that mechanistically links therapeutic antibodies to concurrent small molecule or radiation therapy.
Learn more about Conditioned Cell Immunization

Advances in stem cell research

Raven has established dozens of pure cancer stem cell lines from a variety of cancers. New MAbs are being raised against these lines to test for diagnostic and therapeutic applications.
Learn more about these advances in stem cell research

Information on Cancer Stem Cells and Antibody Therapy

Cancer Stem Cells

Antibody Therapy